Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
Nipro aims to expand the number of medical facilities administering its stem cell therapy Stemirac from the current 17 to 50-60, making the treatment available in all 47 prefectures following its landmark full approval in Japan, CEO Tsuyoshi Yamazaki said…
To read the full story
Related Article
- Nipro’s Stemirac Clinches Full Approval in Japan
November 17, 2026
- Minister Lauds Stemirac after Panel Backs Full Approval
October 19, 2026
- Nipro’s Stemirac Nears 1st Full Nod Conversion for Regenerative Therapy
October 16, 2026
- Japan Panel to Review Full Approval of Nipro’s Stemirac on October 15
October 13, 2026
- Nipro Files for Full Approval of Stemirac Cell Therapy
November 18, 2025
- Nipro Launches Stemirac Manufacturing Facility in Tokyo
June 8, 2020
- Medipal’s Subsidiary to Distribute Stemirac in Japan
April 9, 2019
- MHLW Acknowledges Need to Ponder Rules for “Regenerative Medicines”: Official
February 21, 2019
- Stemirac Fetches 15 Million Yen Price Tag, Peak Sales Put at 3.7 Billion Yen
February 20, 2019
- Nipro to Strive for Stable Supply of Stemirac, 1st Stem Cell Therapy for Spinal Cord Injury
January 7, 2019
- Japan Gives Conditional OK to 1st Stem Cell Therapy for Spinal Cord Injury
December 28, 2018
BUSINESS
- Nipro Eyes 50-60 Stemirac Treatment Sites across Japan after Full Nod
November 20, 2026
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026





